Vectura Group, a British pharmaceutical company focused on inhaled medicines, said on Wednesday it had agreed a 958 million pound ($1.36 billion) takeover by global investment firm The Carlyle Group.
Shareholders will receive 136 pence in cash plus a dividend of 19 pence for each share under the terms of the offer, representing a 32% premium on the ex-dividend closing price of the stock on Tuesday, Vectura said.
Vectura’s Chairman Bruno Angelici said the company had made strong progress since embarking on a strategy in 2019 to become a leading inhalation-focused CDMO, or contract development and manufacturing organisation.
Read more at Reuters
